Metagenomic Next-Generation Sequencing in the Diagnosis of Infectious Fever During Myelosuppression Among Pediatric Patients with Hematological and Neoplastic Diseases
Yang Fu,Xiaohua Zhu,Ping Cao,Chen Shen,Xiaowen Qian,Hui Miao,Yi Yu,Hongsheng Wang,Xiaowen Zhai
DOI: https://doi.org/10.2147/IDR.S379582
2022-09-14
Infection and Drug Resistance
Abstract:Yang Fu, Xiaohua Zhu, Ping Cao, Chen Shen, Xiaowen Qian, Hui Miao, Yi Yu, Hongsheng Wang, Xiaowen Zhai Department of Hematology, National Children's Medical Center Children's Hospital of Fudan University, Shanghai, People's Republic of China Correspondence: Hongsheng Wang; Xiaowen Zhai, Department of Hematology, National Children's Medical Center Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, People's Republic of China, Tel +86 21 64931123, Fax +86 21 64931901, Email ; Purpose: To analyze the contribution of metagenomic next-generation sequencing (mNGS) in the guidance of clinical treatment and outcomes of infection during myelosuppression among children with hematological and neoplastic diseases. Patients and Methods: The clinical data and results of mNGS assay of febrile patients suspected of infection were retrospectively collected. The characteristics of pathogenic microorganisms and clinical course of myelosuppressed children with hematological diseases were summarized. Results: Our study included 70 patients (45 males) with a median age of 5 years (range: 0.5 to 13 y). During the study period, there were 96 events of suspected infection. According to comprehensive clinical diagnosis, 73 blood infections, 43 pneumonia and 2 urinary tract infections occurred. The positive rate of mNGS was significantly higher than that of traditional microbial detection (83.3% vs 17.7%). The main pathogens detected by mNGS were Pseudomonas aeruginosa, Acinetobacter , human herpesvirus, Candida and Aspergillus . The average duration of fever was 4.9 days and 11.6 days ( P < 0.05), and the average cost of anti-infection treatment was RMB ¥ 28,077 and 39,898 ( P < 0.05) among children received mNGS within 48 hours and more than 48 hours after the onset of infection symptoms. Conclusion: mNGS contributes to clinical management of children with infection during myelosuppression, especially among patients with negative traditional microbial detection. Early implementation of mNGS in children with symptoms has a tendency to reduce the time of infection, fever and the cost of treatment. Keywords: metagene, pathogenic microorganism, child, hematology and oncology Infection due to myelosuppression after chemotherapy for malignancies is a common complication and cause of treatment-related death. 1,2 In clinical practice, the traditional identification of pathogens relies heavily on laboratory capacity to detect common pathogenic microorganisms with discrete methods, such as assays for pathogen-specific antibodies, nucleic acids and antigens, and pathogen culture. Although the early diagnosis and correct anti-infection treatment are imperative for patients with myelosuppression, the traditional methods are limited by its low throughput and narrow coverage of pathogen spectrum. It has been shown that more than 60% of the patients with infection cannot receive a pathogen diagnosis. 3–5 This results in a wide practicing of empirical broad-spectrum antimicrobial therapy, which not only increases the risk of antibiotic resistance but also brings related toxic and side effects. 6 Metagenomic next-generation sequencing (mNGS) is an emerging technology for comprehensive analysis of microbial genetic components in patients' samples. In recent years, mNGS has been successfully applied in the detection of pathogens in blood, cerebrospinal fluid (CSF), bronchoalveolar lavage (BAL), urine, and other samples. 7–9 Although mNGS is superior over traditional methods due to its wide coverage, its use is also limited by high cost and low specificity. Recent studies suggested that the efficacy of mNGS in the pathogenic diagnosis of infection is limited in immunocompetent patients. 10,11 However, apparent in immunocompromised patients, especially in the diagnosis of complex, severe infection, mNGS shows advantages over conventional assays in many aspects, including turnaround time, sensitivity, throughput, and mNGS is less affected by prior antibiotic exposure. 12–14 The current study retrospectively reviewed the pathogens identified by mNGS among children clinically diagnosed with infection during myelosuppression. The purpose of this study was to analyze the contribution of mNGS to the guidance of clinical treatment and outcomes in children with hematological and neoplastic disease. The study involves a retrospective patient cohort of consecutive children who presented fever and subjected to mNGS assay in the Department of Hematology, Children's Hospital of Fudan University from July 2019 to March 2021. None of the patients had infection-related symptoms before receiving chemotherapy or immunosuppressive therapy in hospital. Heal -Abstract Truncated-
pharmacology & pharmacy,infectious diseases